查詢結果分析
相關文獻
- 糖尿病腎病變
- Serum Cystatin C Levels in Hypertensive Type 2 Diabetic Nephropathy Patients after Treatment with Angiotensin Converting Enzyme (ACE) Inhibitor Temocapril
- 糖尿病腎病變
- 糖尿病腎病變的診斷與治療
- 糖尿病腎病變之風險預測與藥物治療策略
- 大黃及其有效成分(Emodin)對糖尿病腎病變治療效果之研究
- Effects of Dietary Protein on Urinary Epidermal Growth Factor and Renal Hypertrophy in Diabetic Rats
- The Initial Status and Outcomes of Newly Diagnosed Uremic Patients in Southern Taiwan
- 糖尿病腎病變
- 糖尿病腎病變
頁籤選單縮合
題名 | Serum Cystatin C Levels in Hypertensive Type 2 Diabetic Nephropathy Patients after Treatment with Angiotensin Converting Enzyme (ACE) Inhibitor Temocapril=罹患高血壓的第二型糖尿病腎病受病人在使用血管張力素轉換酶抑制劑Temocapril之後血清Cystatin Chapi的變化 |
---|---|
作者 | Rinnno,Hisaki; Iijima,Toshihiko; Takeda,Yukihiko; Shimizu,Ayumi; Kobata,Mami; Gohda,Tomohito; Saito,Kensuke; Tomino,Yasuhiko; | 書刊名 | 臺灣腎臟醫學會雜誌 |
卷期 | 16:2 2002.06[民91.06] |
頁次 | 頁62-65+95 |
分類號 | 415.6681 |
關鍵詞 | 白蛋白尿; 血清cystain c; 糖尿病腎病; Albuminuria; Serum cystatin c; Tepocapril; Diabetic nephropathy; |
語文 | 英文(English) |
中文摘要 | 本研究的目的為觀察對11例輕度高血壓、微量白蛋白尿的2型糖尿病腎病患者小劑量投用temocapril(2 mg/day),一種長效非巰基血管緊張素轉換酵素(ACE)抑制劑,能否改善白蛋白尿,影響腎小球濾過率、血肌酐(s-Cr)、肌酐清除率(CCr)以及血清Cystatin C等各項指標。對上述患者經口投用temocapril 2毫克每日,總服用時間24個月。服用前及24個月治療結束後,分別檢測血壓、空腹血糖(FPG)、糖化血紅蛋白(HbA1c)、尿白蛋白排泄率、s-Cr、CCr及血清Cystatin C等各項指標。經24個月治療後尿白蛋白排泄率較治療前顯著降低(P<0.05)。雖然治療前後血清Cystatin C及CCr水平均未超出正常範圍,但24個月治療結束後血清Cystatin C水平較治療前明顯升高(P<0.0005),而CCr水平雖較治療前略有下降,但差異無顯著性。本研究顯示temocapril治療後白蛋白尿的改善,可能是其降低了呈輕度高血壓、微量白蛋白尿2型糖尿病腎病患者腎小球濾過率的結果。血清Cystatin C被證明為一種較s-Cr及CCr更為敏感的反映腎小球濾過率的指標。 |
英文摘要 | The purpose of the present study was to determine whether administration of low dose temocapril (2 mg/day), a long-acting non-SH group angiotensin converting enzyme (ACE) inhibitor, might reduce albuminuria and alter glomerular filtration, i.e. serum creatinine (s-Cr), creatinine clearance (CCr) and serum cystatin C, in 11 mildly hypertensive microalbuminuric patients with type 2 diabetic nephropathy. Temocapril was orally administered to these patients at 2mg/day. Duration of administration was 24 months. Before and after 24 months of treatment, blood pressure, fasting plasma glucose (FPG), glycohemoglobin A1c (HbA1c), urinary albumin excretion, s-Cr, CCr and serum cystatin C were evaluated. Levels of urinary albumin excretion after 24 months of treatment were significantly decreased compared with those before treatment (p<0.05). Levels of serum cystatin C and CCr did not exceed the normal range before and after 24 months. However, the levels of serum cystatin C after 24 months of treatment were significantly increased compared with those before treatment (p<0.0005). The levels of CCr after 24 months of treatment were slightly decreased compared with those before treatment, but the difference was not statistically significant. It appears that the reduction of albuminuria after temocapril treatment might be due to that of the glomerular filtration in mildly hypertensive microalbuminuric patients with type 2 diabetic nephropathy. Serum cystatin C was found to be a more sensitive marker for detecting of glomerular filtration than measurement of s-Cr and CCr. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。